Archer Materials Limited’s (ASX: AXE) 100% owned patent application related to its graphene-based biochip technology has progressed to the National Phase of the patent granting procedure and has been filed in the US.
The company has now been assigned a US Application Number, which now allows it to pursue and achieve patent granting in the US for the respective patent application.
The company considers the US as a key strategic jurisdiction to protect and commercialise its IP. The Company has also sought National Phase entry in Australia for the biochip related patent application. As patents are only granted in each country by the relevant national patent office, the National Phase entry is a key requirement in the process for the granting of a patent internationally.
Archer’s patents and patent applications are core company assets that allow for value creation through any future technology development, licensing, monetisation, and transactions for revenue generation.
Patent applications related to the company’s 12CQ chip are progressing in later stages of the patent granting procedures in the US and Europe. Archer recently expanded its access to institutional deep tech infrastructure and hired new personnel to develop its biochip.
The type of knowledge underpinning Archer’s IP is very difficult to acquire and is supported by outcomes of years of R&D that ranks in the top percentiles of peer-reviewed scientific published works globally.
2CQ is a world-first quantum computing processor chip technology The patent granting process and procedures for the additional international patent applications in the jurisdictions of Australia, Hong Kong and Europe continue to progress.
On August 11, Archer announced the granting of a Chinese patent associated with the 12CQ quantum computing chip technology.
Patent protection in China is required for any future commercial operations in China, while giving Archer access to the world’s second largest economy to exploit IP rights related to the 12CQ chip.